by Qingyang Li | Mar 6, 2022 | CURE!
ARO-APOC3 is an investigational therapeutic being evaluated by Arrowhead Pharmaceuticals, Inc. forthe treatment of FCS. A Phase 3 clinical trial, the AROAPOC3-3001 Palisade Study is currently recruitingadults with a clinical diagnosis of FCS at multiple research...
Recent Comments